FR960299A
(me)
|
|
1950-04-15 |
|
|
DE279887C
(me)
|
|
|
|
|
US3830797A
(en)
|
1964-11-05 |
1974-08-20 |
Pennwalt Corp |
Tertiary-aliphatic-alpha-(peracyl)azo compounds
|
US5874424A
(en)
*
|
1995-12-20 |
1999-02-23 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of interleukin-1β converting enzyme
|
US3524858A
(en)
*
|
1967-05-18 |
1970-08-18 |
Warner Lambert Pharmaceutical |
1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid
|
US3443939A
(en)
|
1967-07-24 |
1969-05-13 |
Polaroid Corp |
Differential mobility of color moiety in color transfer
|
DE1908548A1
(de)
|
1968-02-29 |
1970-11-05 |
Warner Lambert Co |
Chinolinderivate
|
BE757639A
(fr)
|
1969-10-17 |
1971-04-16 |
Roussel Uclaf |
Nouveaux derives de la cephalosporine et procede de preparation
|
AT308173B
(de)
|
1970-02-03 |
1973-06-25 |
Maurer Friedrich Soehne |
Überbrückungsvorrichtung für Dehnungsfugen in Brücken od. dgl.
|
US4110355A
(en)
|
1972-12-26 |
1978-08-29 |
Polaroid Corporation |
Anthraquinone compounds useful in photographic processes
|
US3931145A
(en)
|
1972-12-27 |
1976-01-06 |
Gaf Corporation |
Keto-amido containing phenylazophenyl dyestuffs
|
GB1433774A
(en)
|
1973-02-26 |
1976-04-28 |
Allen & Hanburys Ltd |
Heterocyclic compounds apparatus for conveying articles
|
GB1433151A
(en)
|
1973-04-05 |
1976-04-22 |
Allen & Hanburys Ltd |
Benzo-ij-quinolizines
|
FR2281761A1
(fr)
*
|
1974-08-13 |
1976-03-12 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2324304A2
(fr)
|
1975-09-22 |
1977-04-15 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2340092A2
(fr)
|
1976-02-09 |
1977-09-02 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
FR2340735A1
(fr)
*
|
1976-02-11 |
1977-09-09 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
US4221779A
(en)
*
|
1977-06-28 |
1980-09-09 |
Graham Neil B |
Pharmaceutical composition for treating tropical diseases
|
DE2808070A1
(de)
|
1978-02-24 |
1979-08-30 |
Bayer Ag |
Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
|
FR2443467A1
(fr)
|
1978-12-08 |
1980-07-04 |
Roussel Uclaf |
Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
|
US4312870A
(en)
*
|
1979-06-21 |
1982-01-26 |
Ciba-Geigy Corporation |
Pyrazoloquinolines
|
JPS56110612A
(en)
*
|
1980-02-08 |
1981-09-01 |
Yamanouchi Pharmaceut Co Ltd |
Readily disintegrable and absorbable compression molded article of slightly soluble drug
|
US4390541A
(en)
|
1980-12-19 |
1983-06-28 |
Lilly Industries Limited |
Quinolone derivatives and their use in a method of controlling an immediate hypersensitivity disease
|
HU190796B
(en)
*
|
1981-06-12 |
1986-11-28 |
Roussel Uclaf,Fr |
Process for producing n-dihydrothiazolyl-3-quinoline-carboxamide derivatives
|
FR2509728A1
(fr)
*
|
1981-07-17 |
1983-01-21 |
Roussel Uclaf |
Nouveaux derives de la quinoleine, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
|
US4638067A
(en)
|
1982-09-09 |
1987-01-20 |
Warner-Lambert Co. |
Antibacterial agents
|
US5281612A
(en)
|
1982-09-09 |
1994-01-25 |
Warner-Lambert Company |
Naphthyridine antibacterial agents
|
FR2537140B1
(fr)
|
1982-12-07 |
1986-07-18 |
Roussel Uclaf |
Nouveaux derives de la 4-hydroxy-3-quinoleine carboxamide, leur sels, procede de preparation, application a titre de medicaments, et compositions les renfermant
|
SU1360584A3
(ru)
|
1983-08-12 |
1987-12-15 |
Варнер-Ламберт Компани (Фирма) |
Способ получени нафтиридинхинолин-или бензоксазинкарбоновых кислот или их фармацевтически допустимых солей присоединени кислоты
|
US4845105A
(en)
*
|
1984-10-30 |
1989-07-04 |
Roussel Uclaf |
4-OH-quinoline carboxylic acid amides having analgesic and anti-inflammatory activity
|
EP0180548B1
(de)
|
1984-11-01 |
1989-06-28 |
Ciba-Geigy Ag |
Gegen Lichteinwirkung stabilisierte Ueberzugsmittel
|
US4687539A
(en)
|
1986-10-29 |
1987-08-18 |
International Business Machines Corp. |
End point detection and control of laser induced dry chemical etching
|
DE3702393A1
(de)
*
|
1987-01-28 |
1988-08-11 |
Bayer Ag |
8-cyano-1-cyclopropyl-1,4-dihydro-4-oxo- 3-chinolincarbonsaeuren, verfahren zu ihrer herstellung und diese enthaltende antibakterielle mittel
|
DD279887A1
(de)
|
1987-07-03 |
1990-06-20 |
Inst Pharmakologische Forschun |
Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
|
US4777252A
(en)
*
|
1987-08-13 |
1988-10-11 |
E. R. Squibb & Sons, Inc. |
2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
|
DE3827253A1
(de)
|
1987-08-20 |
1989-03-02 |
Sandoz Ag |
Ester und amide von cyclischen carbonsaeuren und cyclischen alkoholen und aminen sowie verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
|
HU206494B
(en)
|
1987-08-27 |
1992-11-30 |
Sumitomo Chemical Co |
Process for producing 3-fluoro-4-amino-phenol
|
DE3731516A1
(de)
|
1987-09-18 |
1989-03-30 |
Bayer Ag |
N-aryl-stickstoffheterocyclen
|
DE3811341A1
(de)
*
|
1987-10-09 |
1989-04-27 |
Bayer Ag |
In 7-stellung c-verknuepfte chinolon- und 1,8-naphthyridin-4-on-carbonsaeure und ein verfahren zu ihrer herstellung
|
US4786644A
(en)
*
|
1987-11-27 |
1988-11-22 |
Hoechst-Roussel Pharmaceuticals Inc. |
1-aryl-3-quinolinecarboxamide
|
DE3808118A1
(de)
|
1988-03-11 |
1989-09-21 |
Bayer Ag |
Verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
|
DE3808117A1
(de)
|
1988-03-11 |
1989-09-21 |
Bayer Ag |
N-cyclopropylaniline und deren verwendung in verfahren zur herstellung von 1-cyclopropyl-chinoloncarbonsaeuren und deren derivaten
|
DE3816119A1
(de)
|
1988-05-11 |
1989-11-23 |
Bayer Ag |
7-substituierte chinolon- und naphthyridoncarbonsaeure-derivate
|
JPH01287066A
(ja)
|
1988-05-13 |
1989-11-17 |
Fujimoto Seiyaku Kk |
新規なアントラニル酸誘導体
|
JPH01168920U
(me)
|
1988-05-18 |
1989-11-29 |
|
|
DK273689A
(da)
*
|
1988-06-06 |
1989-12-07 |
Sanofi Sa |
4-amino-3-carboxyquinoliner og -naphthyridiner, fremgangsmaade til deres fremstilling og anvendelse deraf i laegemidler
|
DE3827221A1
(de)
|
1988-08-11 |
1990-02-15 |
Bayer Ag |
Substituierte n-phenyl-stickstoff- bzw. stickstoff-schwefel-heterocyclen, verfahren sowie entsprechende heterocyclische phenolderivate, phenyliso(thio)cyanate und -carbamate als zwischenprodukte zu ihrer herstellung, ihre verwendung in herbiziden und pflanzenwuchsregulierenden mitteln
|
US5491139A
(en)
*
|
1988-10-24 |
1996-02-13 |
The Procter & Gamble Company |
Antimicrobial quinolonyl lactams
|
DE3903799A1
(de)
|
1989-02-09 |
1990-08-16 |
Bayer Ag |
N-aryl-stickstoffheterocyclen
|
JPH0334977A
(ja)
|
1989-06-29 |
1991-02-14 |
Yoshitomi Pharmaceut Ind Ltd |
イミダゾリルベンゾラクタム化合物
|
DE3924052A1
(de)
|
1989-07-21 |
1991-01-24 |
Bayer Ag |
N- (indol-6-yl)-heterocyclen
|
EP0418596A3
(en)
|
1989-09-21 |
1991-10-23 |
American Cyanamid Company |
Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
|
GB2236751B
(en)
|
1989-10-14 |
1993-04-28 |
Wyeth John & Brother Ltd |
Heterocyclic compounds
|
LU87611A1
(fr)
*
|
1989-10-20 |
1991-05-07 |
Oreal |
Composition tinctoriale pour fibres keratiniques contenant des precurseurs de colorants par oxydation et des coupleurs amino indoliques,procedes de teinture mettant en oeuvre ces compositions et composes nouveaux
|
FR2659552B2
(fr)
|
1989-10-20 |
1994-11-04 |
Oreal |
Procede de teinture des fibres keratiniques avec des aminoindoles, composition et dispositif de mise en óoeuvre.
|
US5254135A
(en)
|
1989-10-20 |
1993-10-19 |
L'oreal |
Methods for dyeing keratinous fibres with aminoindoles, compositions and devices for use
|
US5304121A
(en)
|
1990-12-28 |
1994-04-19 |
Boston Scientific Corporation |
Drug delivery system making use of a hydrogel polymer coating
|
FR2662713B1
(fr)
|
1990-05-29 |
1994-04-08 |
Oreal |
Procede de teinture de fibres keratiniques avec un aminoindole associe a un derive quinonique.
|
DE4017516A1
(de)
|
1990-05-31 |
1991-12-05 |
Wella Ag |
Oxidationshaarfaerbemittel mit einem gehalt an 3-aminophenol-derivaten, verfahren zum oxidativen faerben von haaren sowie neue 3-aminophenol-derivate
|
US5409503A
(en)
|
1990-05-31 |
1995-04-25 |
Wella Aktiengesellschaft |
Oxidation hair dye with a content of 5-aminophenyl derivatives, process for oxidative dyeing of hair and new 5-aminophenol derivatives
|
DE4026530A1
(de)
|
1990-08-22 |
1992-02-27 |
Basf Ag |
Synergistische mittel zur regulierung des pflanzenwachstums
|
EP0550464A1
(en)
*
|
1990-09-07 |
1993-07-14 |
Schering Corporation |
Antiviral compounds and antihypertensive compounds
|
AU8665991A
(en)
*
|
1990-09-07 |
1992-03-30 |
Schering Corporation |
Antiviral compounds and antihypertensive compounds
|
US5175151A
(en)
*
|
1990-09-07 |
1992-12-29 |
Schering Corporation |
Antiviral compounds and antihypertensive compounds
|
JPH04171521A
(ja)
|
1990-11-05 |
1992-06-18 |
Fujitsu Ltd |
タッチパネル
|
IL100917A0
(en)
|
1991-02-16 |
1992-11-15 |
Fisons Plc |
Pyridinone and pyrimidinone derivatives,their preparation and pharmaceutical compositions containing them
|
RU1796623C
(ru)
|
1991-03-11 |
1993-02-23 |
Институт химии Башкирского научного центра Уральского отделения АН СССР |
Способ получени этилового эфира 6,7-дифтор-1,4-дигидро-4-оксо-3-хинолинкарбоновой кислоты
|
CA2065106A1
(en)
|
1991-04-04 |
1992-10-05 |
Junichi Fukawa |
Silver halide photographic light-sensitive material and photographic product for film-making process
|
US5938792A
(en)
|
1991-04-18 |
1999-08-17 |
L'oreal |
Process for dyeing keratinous fibers with aminoindoles and oxidation dye precursors at basic Ph's and dyeing agents
|
FR2675380A1
(fr)
|
1991-04-18 |
1992-10-23 |
Oreal |
Procede de teinture des fibres keratiniques avec des aminoindoles, a ph basique, compositions mises en óoeuvre et nouveaux composes.
|
GB9108547D0
(en)
|
1991-04-22 |
1991-06-05 |
Fujisawa Pharmaceutical Co |
Quinoline derivatives
|
SK117793A3
(en)
|
1991-04-29 |
1994-05-11 |
Merck & Co Inc |
Optimized tablet formulation
|
CA2075154A1
(en)
*
|
1991-08-06 |
1993-02-07 |
Neelakantan Balasubramanian |
Peptide aldehydes as antithrombotic agents
|
JPH05345780A
(ja)
*
|
1991-12-24 |
1993-12-27 |
Kumiai Chem Ind Co Ltd |
ピリミジンまたはトリアジン誘導体及び除草剤
|
JPH05184185A
(ja)
|
1991-12-27 |
1993-07-23 |
Copal Electron Co Ltd |
Dcブラシレスモータ速度制御方法
|
JPH05231760A
(ja)
|
1992-02-24 |
1993-09-07 |
Sanyo Electric Co Ltd |
冷蔵庫の温度制御装置
|
EP0641204B1
(en)
*
|
1992-05-20 |
2000-08-16 |
Merck & Co. Inc. |
17-ethers and thioethers of 4-aza-steroids
|
EP0649306B1
(en)
*
|
1992-05-20 |
2001-01-10 |
Merck & Co. Inc. |
Ester derivatives of 4-aza-steroids
|
JPH0672979A
(ja)
|
1992-06-08 |
1994-03-15 |
Hiroyoshi Hidaka |
アミノベンジル誘導体
|
RU2047614C1
(ru)
|
1992-06-15 |
1995-11-10 |
Джон Вайс энд Бразер Лимитед |
Гетероциклические соединения, или их фармацевтически приемлемые аддитивные соли кислоты, или n-оксид гетероциклического соединения, или его аддитивная соль кислоты
|
US5352690A
(en)
*
|
1992-07-01 |
1994-10-04 |
Eli Lilly And Company |
1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists
|
JP2718830B2
(ja)
*
|
1992-07-10 |
1998-02-25 |
ラボラトワール、グラクソ、ソシエテ、アノニム |
アニリド誘導体
|
US5322847A
(en)
*
|
1992-11-05 |
1994-06-21 |
Pfizer Inc. |
Azabenzimidazoles in the treatment of asthma, arthritis and related diseases
|
WO1994014797A1
(en)
|
1992-12-23 |
1994-07-07 |
Smithkline Beecham Corporation |
Quinoline compounds and the treatment of leucotriene related diseases therewith
|
JPH06278180A
(ja)
|
1993-03-26 |
1994-10-04 |
Mitsubishi Heavy Ind Ltd |
型盤開限度ストッパ装置
|
US5750754A
(en)
*
|
1993-03-29 |
1998-05-12 |
Zeneca Limited |
Heterocyclic compounds
|
JP3760474B2
(ja)
*
|
1993-04-22 |
2006-03-29 |
ダイキン工業株式会社 |
電気エネルギーを発生させる方法、装置およびそれに用いるn−f結合を有する化合物
|
US5716981A
(en)
|
1993-07-19 |
1998-02-10 |
Angiogenesis Technologies, Inc. |
Anti-angiogenic compositions and methods of use
|
JPH0733729A
(ja)
|
1993-07-26 |
1995-02-03 |
Kirin Brewery Co Ltd |
N−シアノ−n′−置換−アリールカルボキシイミダミド化合物の製造法
|
JPH0782498A
(ja)
|
1993-09-17 |
1995-03-28 |
Fuji Photo Film Co Ltd |
ビスアゾ化合物
|
IL111266A
(en)
*
|
1993-10-22 |
2002-03-10 |
Zeneca Ltd |
2-HETEROARYL OR 2-ARYLPYRIDAZINO [4,5-b] QUINOLINE - 1, 10 - DIONES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
|
JPH07179407A
(ja)
|
1993-11-12 |
1995-07-18 |
Green Cross Corp:The |
新規縮合環系化合物またはその塩、およびその医薬用途
|
JP3319838B2
(ja)
|
1993-11-12 |
2002-09-03 |
本田技研工業株式会社 |
車両のトラクション制御装置
|
EP0746561B1
(en)
*
|
1994-02-25 |
1999-04-28 |
Laboratorios Aranda, S.A. De C.V. (Mx/Mx) |
Quinolonylcarboxamidocephalosporin derivatives and pharmaceutical compositions containing them
|
FR2720397B1
(fr)
*
|
1994-05-24 |
1996-08-23 |
Laphal Laboratoires Sa |
Nouveaux oxathiolanes, leur procédé de préparation et les compositions pharmaceutiques qui en renferment.
|
ITMI941099A1
(it)
|
1994-05-27 |
1995-11-27 |
Smithkline Beecham Farma |
Derivati chinolinici
|
NZ287442A
(en)
|
1994-05-27 |
1998-05-27 |
Smithkline Beecham Spa |
4-substituted quinoline derivatives; medicaments; use as an nk3 receptor antagonist
|
EP0705835A1
(de)
|
1994-09-01 |
1996-04-10 |
Ciba-Geigy Ag |
Oxa- oder thiaaliphatisch überbrückte Chinoxalin-2,3-dione
|
WO1996015099A1
(en)
|
1994-11-09 |
1996-05-23 |
Novo Nordisk A/S |
Heterocyclic compounds, their preparation and use
|
JP3556982B2
(ja)
|
1994-12-15 |
2004-08-25 |
小島プレス工業株式会社 |
ラゲ−ジトレイ
|
AU4314196A
(en)
*
|
1994-12-21 |
1996-07-10 |
Yamanouchi Pharmaceutical Co., Ltd. |
Solid composition with improved solubility and absorbability
|
GB9501567D0
(en)
*
|
1995-01-26 |
1995-03-15 |
Pharmacia Spa |
Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
|
JPH08208824A
(ja)
|
1995-01-31 |
1996-08-13 |
Idemitsu Kosan Co Ltd |
ポリカーボネートの製造方法
|
US6099562A
(en)
|
1996-06-13 |
2000-08-08 |
Schneider (Usa) Inc. |
Drug coating with topcoat
|
JPH08301849A
(ja)
|
1995-05-01 |
1996-11-19 |
Takeda Chem Ind Ltd |
ヘテロ環化合物およびその製造法
|
JPH0971534A
(ja)
|
1995-06-26 |
1997-03-18 |
Tanabe Seiyaku Co Ltd |
医薬組成物
|
DE19601142A1
(de)
|
1995-07-13 |
1997-01-16 |
Agfa Gevaert Ag |
Verfahren zur Erzeugung eines farbigen Bildes
|
CA2225555A1
(en)
*
|
1995-08-02 |
1997-02-13 |
Chiroscience Limited |
Quinolones and their therapeutic use
|
PT841929E
(pt)
|
1995-08-02 |
2003-09-30 |
Darwin Discovery Ltd |
Quinolonas e sua utilizacao terapeutica
|
DE19532235A1
(de)
|
1995-08-31 |
1997-03-06 |
Keppler Bernhard K Priv Doz Dr |
An Phosphonsäuren gekoppelte antibakteriell wirksame Verbindungen zur Therapie von Infektionen im Bereich des Knochens
|
ATE223902T1
(de)
*
|
1995-10-19 |
2002-09-15 |
Takeda Chemical Industries Ltd |
Chinolinderivate als gnrh antagonisten
|
GB9526546D0
(en)
|
1995-12-23 |
1996-02-28 |
Pfizer Ltd |
Compounds useful in therapy
|
WO1997030999A1
(en)
|
1996-02-21 |
1997-08-28 |
Darwin Discovery Limited |
Quinolones and their therapeutic use
|
US6215016B1
(en)
*
|
1996-03-27 |
2001-04-10 |
Toray Industries, Inc. |
Ketone derivatives and medical application thereof
|
DE19615262A1
(de)
*
|
1996-04-18 |
1997-10-23 |
Bayer Ag |
Heteroverknüpfte Phenylglycinolamide
|
BR9709105A
(pt)
*
|
1996-05-20 |
1999-08-03 |
Darwin Discovery Ltd |
Sulfonamidas de quinolina como inibidoras de tnf e como inobidoras de pde-iv
|
KR20000065219A
(ko)
*
|
1996-05-20 |
2000-11-06 |
마르크 젠너 |
티엔에프 저해제 및 피디이-4 저해제로서의 퀴놀린 카르복사미드
|
PL330814A1
(en)
*
|
1996-06-20 |
1999-06-07 |
Regents Board Of |
Compounds for and methods of delivering pharmaceutical preparations and their application
|
DE69721541T2
(de)
*
|
1996-07-23 |
2004-03-18 |
Neurogen Corp., Branford |
Einige amido-und amino-substituierte benzylaminderivate: eine neue klasse von neuropeptid y1 spezifischen liganden
|
GB9717576D0
(en)
|
1997-08-19 |
1997-10-22 |
Xenova Ltd |
Pharmaceutical compounds
|
US6069151A
(en)
*
|
1996-11-06 |
2000-05-30 |
Darwin Discovery, Ltd. |
Quinolines and their therapeutic use
|
DE19651099A1
(de)
|
1996-12-09 |
1998-06-10 |
Consortium Elektrochem Ind |
Mehrkomponentensystem zum Verändern, Abbau oder Bleichen von Lignin, ligninhaltigen Materialien oder ähnlichen Stoffen sowie Verfahren zu seiner Anwendung
|
AU6209098A
(en)
|
1997-01-15 |
1998-08-07 |
Novartis Ag |
Herbicidal agent
|
US5948814A
(en)
|
1997-02-20 |
1999-09-07 |
The Curators Of The University Of Missouri |
Genistein for the treatment of cystic fibrosis
|
ZA986594B
(en)
|
1997-07-25 |
1999-01-27 |
Abbott Lab |
Urokinase inhibitors
|
US6258822B1
(en)
*
|
1997-08-06 |
2001-07-10 |
Abbott Laboratories |
Urokinase inhibitors
|
PT901786E
(pt)
*
|
1997-08-11 |
2007-08-07 |
Pfizer Prod Inc |
Disperções farmacêuticas sólidas com biodisponibilidade melhorada
|
CZ295461B6
(cs)
|
1997-08-26 |
2005-08-17 |
Aventis Pharmaceuticals Inc. |
Farmaceutický prostředek ve formě dvouvrstvé tablety
|
US20020017295A1
(en)
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6429207B1
(en)
*
|
1997-11-21 |
2002-08-06 |
Nps Pharmaceuticals, Inc. |
Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
|
SK286564B6
(sk)
|
1997-12-22 |
2009-01-07 |
Bayer Corporation |
Substituované arylmočoviny ako inhibítory rafkinázy a farmaceutický prípravok s ich obsahom
|
WO1999046267A1
(en)
|
1998-03-12 |
1999-09-16 |
Novo Nordisk A/S |
Modulators of protein tyrosine phosphatases (ptpases)
|
KR20010041811A
(ko)
|
1998-03-12 |
2001-05-25 |
온토젠 코포레이션 |
단백질 티로신 포스파타제의 조절제
|
DE19818614A1
(de)
*
|
1998-04-20 |
1999-10-21 |
Basf Ag |
Neue substituierte Amide, deren Herstellung und Anwendung
|
JP2000016982A
(ja)
|
1998-06-30 |
2000-01-18 |
Kumiai Chem Ind Co Ltd |
キノリン誘導体及びこれを有効成分とする除草剤
|
US6133285A
(en)
*
|
1998-07-15 |
2000-10-17 |
Active Biotech Ab |
Quinoline derivatives
|
CA2338827A1
(en)
*
|
1998-07-28 |
2000-02-10 |
Hideo Takaishi |
Fused heterocyclic dicarboxylic acids diamide derivatives or salts thereof, herbicide and method for using the same
|
WO2000008019A1
(en)
*
|
1998-08-03 |
2000-02-17 |
Applied Research Systems Ars Holding N.V. |
Process for the synthesis of (1h)-benzo[c]quinolizin-3-ones derivatives
|
US7001770B1
(en)
|
1998-10-15 |
2006-02-21 |
Canji, Inc. |
Calpain inhibitors and their applications
|
CA2348267A1
(en)
|
1998-10-29 |
2000-05-11 |
Henry H. Gu |
Novel inhibitors of impdh enzyme
|
FR2786483B1
(fr)
*
|
1998-12-01 |
2001-02-16 |
Rhodia Chimie Sa |
Procede de preparation de 4-hydroxyquinoleines et/ou formes tautomeres
|
US6248736B1
(en)
|
1999-01-08 |
2001-06-19 |
Pharmacia & Upjohn Company |
4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
|
US6248739B1
(en)
|
1999-01-08 |
2001-06-19 |
Pharmacia & Upjohn Company |
Quinolinecarboxamides as antiviral agents
|
ATE289586T1
(de)
|
1999-03-01 |
2005-03-15 |
Pfizer Prod Inc |
Oxamsäuren mit einer cyanogruppe als liganden für den thyroidrezeptor
|
JP2000256358A
(ja)
|
1999-03-10 |
2000-09-19 |
Yamanouchi Pharmaceut Co Ltd |
ピラゾール誘導体
|
AU4818000A
(en)
|
1999-05-06 |
2000-11-21 |
Neurogen Corporation |
Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
|
CO5200844A1
(es)
|
1999-09-17 |
2002-09-27 |
Novartis Ag |
Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
|
RS51019B
(sr)
*
|
1999-10-25 |
2010-10-31 |
Active Biotech Ab. |
Lekovi za lečenje malignih tumora
|
SE0002320D0
(sv)
|
1999-10-25 |
2000-06-21 |
Active Biotech Ab |
Malignant tumors
|
ATE312820T1
(de)
|
1999-10-28 |
2005-12-15 |
Trine Pharmaceuticals Inc |
Pumpeninhibitoren zur freisetzung von medikamenten
|
AU1302301A
(en)
|
1999-11-08 |
2001-06-06 |
Sankyo Company Limited |
Nitrogenous heterocycle derivatives
|
JP2001199965A
(ja)
|
1999-11-08 |
2001-07-24 |
Sankyo Co Ltd |
含窒素複素環誘導体
|
UA75055C2
(uk)
|
1999-11-30 |
2006-03-15 |
Пфайзер Продактс Інк. |
Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
|
GT200000203A
(es)
*
|
1999-12-01 |
2002-05-24 |
|
Compuestos, composiciones y metodos para estimular el crecimiento y elongacion de neuronas.
|
JP2003519146A
(ja)
|
1999-12-23 |
2003-06-17 |
アストラゼネカ・アクチエボラーグ |
痛みの処置のための方法および組成物
|
JP2001233859A
(ja)
|
2000-02-23 |
2001-08-28 |
Yamanouchi Pharmaceut Co Ltd |
抗ヘリコバクター・ヒ゜ロリ化合物の新規製造法及びその中間体
|
US20010053791A1
(en)
|
2000-03-16 |
2001-12-20 |
Babcock Walter C. |
Glycogen phosphorylase inhibitor
|
GB0011409D0
(en)
*
|
2000-05-11 |
2000-06-28 |
Smithkline Beecham Plc |
Novel compounds
|
US6657085B2
(en)
|
2000-05-17 |
2003-12-02 |
Syngenta Crop Protection, Inc. |
Process for the preparation of aniline compounds
|
US6800297B2
(en)
*
|
2000-06-15 |
2004-10-05 |
Acusphere, Inc. |
Porous COX-2 inhibitor matrices and methods of manufacture thereof
|
WO2002003938A1
(en)
|
2000-06-29 |
2002-01-17 |
Clairol Incorporated |
Iodo-containing organic couplers for use in oxidative hair dyeing
|
CA2429008A1
(en)
|
2000-07-13 |
2003-01-09 |
Takeda Chemical Industries, Ltd. |
Lipid-rich plaque regressing agents
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
WO2002012189A1
(fr)
*
|
2000-08-09 |
2002-02-14 |
Mitsubishi Pharma Corporation |
Composes amide bicycliques condenses et utilisations medicales associees
|
AU2002212102A1
(en)
|
2000-11-08 |
2002-05-21 |
Aeromatic-Fielder Ag |
A process for production of particles for pharmaceutical compositions having increased bioavailability
|
JP2002212179A
(ja)
|
2001-01-15 |
2002-07-31 |
Wakunaga Pharmaceut Co Ltd |
新規アニリド誘導体又はその塩及びこれを含有する医薬
|
GB2372986A
(en)
|
2001-01-17 |
2002-09-11 |
Xenova Ltd |
2-oxo, 4-hydroxy pyrroles and quinolines
|
GB0102687D0
(en)
*
|
2001-02-02 |
2001-03-21 |
Pharmacia & Upjohn Spa |
Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
|
US20100074949A1
(en)
|
2008-08-13 |
2010-03-25 |
William Rowe |
Pharmaceutical composition and administration thereof
|
TWI243164B
(en)
*
|
2001-02-13 |
2005-11-11 |
Aventis Pharma Gmbh |
Acylated indanyl amines and their use as pharmaceuticals
|
DE10108271A1
(de)
*
|
2001-02-21 |
2002-08-22 |
Schering Ag |
Chinolin-, Isochinolin- und Phthalazinderivate als Antagonisten des Gonadotropin freisetzenden Hormons
|
US6515001B2
(en)
*
|
2001-03-05 |
2003-02-04 |
Chemokine Therapeutic Corporation |
IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
|
DE10110750A1
(de)
*
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
|
ATE372768T1
(de)
|
2001-03-29 |
2007-09-15 |
Lilly Co Eli |
N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste
|
JP2002296731A
(ja)
|
2001-03-30 |
2002-10-09 |
Fuji Photo Film Co Ltd |
熱現像カラー画像記録材料
|
US6878713B2
(en)
*
|
2001-04-25 |
2005-04-12 |
Wockhardt Limited |
Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments
|
JP2002322054A
(ja)
|
2001-04-26 |
2002-11-08 |
Dai Ichi Seiyaku Co Ltd |
薬剤排出ポンプ阻害薬
|
JP2002322154A
(ja)
|
2001-04-27 |
2002-11-08 |
Dai Ichi Seiyaku Co Ltd |
抗真菌化合物
|
JP2002326935A
(ja)
|
2001-05-07 |
2002-11-15 |
Sankyo Co Ltd |
含窒素複素環誘導体を含有する医薬
|
CN1511151A
(zh)
|
2001-05-24 |
2004-07-07 |
֮����ҩ��ʽ���� |
3-喹啉-2(1h)-亚基二氢吲哚-2-酮衍生物
|
JP2003012667A
(ja)
|
2001-06-26 |
2003-01-15 |
Rrf Kenkyusho:Kk |
キノリンカルボキサミド骨格を有する抗菌剤
|
AU2002349882A1
(en)
|
2001-09-21 |
2003-04-01 |
Case Western Reserve University |
Q4n2neg2 enhances cftr activity
|
MXPA04002537A
(es)
*
|
2001-10-12 |
2004-05-31 |
Warner Lambert Co |
Alquinos como inhibidores de metaloproteinasa de matriz.
|
JP3748222B2
(ja)
|
2001-11-07 |
2006-02-22 |
株式会社リコー |
可逆性感熱発色組成物及びそれを用いた可逆性記録媒体
|
CN1612866A
(zh)
|
2001-11-14 |
2005-05-04 |
特瓦制药工业有限公司 |
无定形和结晶形的氯沙坦钾及其制备方法
|
TW200300349A
(en)
|
2001-11-19 |
2003-06-01 |
Sankyo Co |
A 4-oxoqinoline derivative
|
CA2468015A1
(en)
*
|
2001-11-27 |
2003-06-05 |
Merck & Co., Inc. |
2-aminoquinoline compounds
|
WO2003049702A2
(en)
*
|
2001-12-10 |
2003-06-19 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
AR038375A1
(es)
|
2002-02-01 |
2005-01-12 |
Pfizer Prod Inc |
Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
|
BR0307515A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Método para fabricar dispersões de drogas amorfas sólidas secas por aspersão homogêneas usando bicos de pressão
|
JP2003238413A
(ja)
|
2002-02-14 |
2003-08-27 |
Kyowa Hakko Kogyo Co Ltd |
ステロイドスルファターゼ阻害剤
|
DE20221945U1
(de)
*
|
2002-03-15 |
2009-10-15 |
Wella Aktiengesellschaft |
Chinolinium-Salze enthaltende Färbemittel
|
US6930131B2
(en)
*
|
2002-04-10 |
2005-08-16 |
Wyeth |
Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM)
|
US7718663B2
(en)
*
|
2002-04-26 |
2010-05-18 |
Nippon Shinyaku Co., Ltd. |
Quinazoline derivatives and medicaments
|
US7037913B2
(en)
*
|
2002-05-01 |
2006-05-02 |
Bristol-Myers Squibb Company |
Bicyclo 4.4.0 antiviral derivatives
|
AU2003229043B2
(en)
*
|
2002-05-14 |
2008-12-04 |
The Regents Of The University Of California |
Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
|
US7524861B2
(en)
*
|
2002-05-14 |
2009-04-28 |
David Frank Hayman |
Process for the preparation of a hydrate of an anthranilic acid derivative
|
SE0201669D0
(sv)
|
2002-06-03 |
2002-06-03 |
Pharmacia Ab |
New formulation and use thereof
|
WO2004006858A2
(en)
*
|
2002-07-15 |
2004-01-22 |
Myriad Genetics, Inc |
Compounds, compositions, and methods employing same
|
US20040033959A1
(en)
*
|
2002-07-19 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pharmaceutical compositions for hepatitis C viral protease inhibitors
|
MXPA05001642A
(es)
*
|
2002-08-13 |
2005-04-25 |
Warner Lambert Co |
Derivados de naftaleno como inhibidores de metaloproteinasas de matriz.
|
TWI314041B
(en)
|
2002-10-21 |
2009-09-01 |
Sankyo Agro Co Ltd |
Quinolyl-3-carboxamide compound
|
PE20040844A1
(es)
|
2002-11-26 |
2004-12-30 |
Novartis Ag |
Acidos fenilaceticos y derivados como inhibidores de la cox-2
|
JP2004189738A
(ja)
|
2002-11-29 |
2004-07-08 |
Nippon Nohyaku Co Ltd |
置換アニリド誘導体、その中間体及び農園芸用薬剤並びにその使用方法
|
EP1601657A1
(en)
|
2003-03-12 |
2005-12-07 |
Vertex Pharmaceuticals Incorporated |
Pyrazole modulators of atp-binding cassette transporters
|
WO2004105779A2
(en)
|
2003-05-27 |
2004-12-09 |
Cesare Montecucco |
Green tea and oplyphenol inhibitors of bacterial proteases
|
DE602004022819D1
(de)
|
2003-06-06 |
2009-10-08 |
Vertex Pharma |
Von atp-bindende kassette transportern
|
KR20060041254A
(ko)
*
|
2003-07-24 |
2006-05-11 |
아스텔라스세이야쿠 가부시키가이샤 |
퀴놀론 유도체 또는 그의 염
|
CN1191252C
(zh)
|
2003-08-11 |
2005-03-02 |
中国药科大学 |
3-位取代的喹诺酮衍生物及其在药学上的应用
|
CA2537841A1
(en)
|
2003-09-06 |
2005-03-24 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US20050059035A1
(en)
|
2003-09-09 |
2005-03-17 |
Quest Diagnostics Incorporated |
Methods and compositions for the amplification of mutations in the diagnosis of cystic fibrosis
|
PT2821067T
(pt)
|
2003-09-12 |
2017-12-01 |
Amgen Inc |
Formulação de cinacalcet de dissolução rápida
|
US7223759B2
(en)
|
2003-09-15 |
2007-05-29 |
Anadys Pharmaceuticals, Inc. |
Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds
|
WO2005035514A2
(en)
|
2003-10-08 |
2005-04-21 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups
|
WO2005046696A1
(ja)
|
2003-11-14 |
2005-05-26 |
Ajinomoto Co., Inc. |
フェニルアラニン誘導体の固体分散体または固体分散体医薬製剤
|
CA2545719A1
(en)
|
2003-11-14 |
2005-06-02 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters
|
US20050208095A1
(en)
*
|
2003-11-20 |
2005-09-22 |
Angiotech International Ag |
Polymer compositions and methods for their use
|
CA2548281C
(en)
|
2003-12-09 |
2013-11-12 |
Medcrystalforms, Llc |
Method of preparation of mixed phase co-crystals with active agents
|
US20070196395A1
(en)
|
2003-12-12 |
2007-08-23 |
Mackerell Alexander |
Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain
|
JP2007519756A
(ja)
*
|
2004-01-30 |
2007-07-19 |
アンジオテック インターナショナル アーゲー |
拘縮を治療するための組成物および方法
|
EP1716122B1
(en)
|
2004-01-30 |
2017-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
US7977322B2
(en)
|
2004-08-20 |
2011-07-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
SE0400235D0
(sv)
*
|
2004-02-06 |
2004-02-06 |
Active Biotech Ab |
New composition containing quinoline compounds
|
WO2005094805A1
(ja)
|
2004-04-01 |
2005-10-13 |
Institute Of Medicinal Molecular Design. Inc. |
イミン誘導体及びアミド誘導体
|
JP2006206612A
(ja)
|
2004-05-27 |
2006-08-10 |
Ono Pharmaceut Co Ltd |
固形製剤用組成物
|
WO2005120497A2
(en)
*
|
2004-06-04 |
2005-12-22 |
The Regents Of The University Of California |
Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
|
US20140343098A1
(en)
|
2004-06-24 |
2014-11-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
CN107501099B
(zh)
|
2004-06-24 |
2021-03-19 |
沃泰克斯药物股份有限公司 |
Atp-结合弹夹转运蛋白的调控剂
|
US8354427B2
(en)
|
2004-06-24 |
2013-01-15 |
Vertex Pharmaceutical Incorporated |
Modulators of ATP-binding cassette transporters
|
EP1771158A4
(en)
|
2004-07-02 |
2008-03-12 |
Advancis Pharmaceutical Corp |
TABLET FOR PULSED DELIVERY
|
US20060035890A1
(en)
|
2004-08-10 |
2006-02-16 |
Amit Banerjee |
Compounds and methods for the treatment of ubiquitin conjugating disorders
|
JP5323354B2
(ja)
|
2004-09-21 |
2013-10-23 |
トーマス ジョセフ ラリー, |
多目的生体材料組成物
|
CA2588607A1
(en)
|
2004-11-23 |
2006-06-01 |
Ptc Therapeutics, Inc. |
Carbazole, carboline and indole derivatives useful in the inhibition of vegf production
|
EP2363128B1
(en)
|
2005-03-11 |
2016-02-17 |
Vertex Pharmaceuticals Incorporated |
Indole modulators of ATP-binding cassette transporters
|
KR20070114820A
(ko)
|
2005-03-18 |
2007-12-04 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
돌연변이-cftr 처리를 보정하는데 활성을 가지는화합물 및 이것의 사용
|
EP1875911A4
(en)
|
2005-04-28 |
2010-03-03 |
Eisai R&D Man Co Ltd |
STABILIZED COMPOSITION
|
US8822451B2
(en)
|
2005-05-24 |
2014-09-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
WO2007021982A2
(en)
|
2005-08-11 |
2007-02-22 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
ZA200802172B
(en)
|
2005-08-11 |
2009-06-24 |
Vertex Pharma |
Modulators of cystic fibrosis transmembrane conductance regulator
|
CA2624683A1
(en)
|
2005-10-06 |
2007-04-19 |
Vertex Pharmaceuticals Incorporated |
Modulators of atp-binding cassette transporters
|
EP2395002B1
(en)
|
2005-11-08 |
2014-06-18 |
Vertex Pharmaceuticals Inc. |
Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters.
|
US20120232059A1
(en)
|
2005-11-08 |
2012-09-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette Transporters
|
US20080057047A1
(en)
|
2005-11-29 |
2008-03-06 |
Benedikt Sas |
Use of bacillus amyloliquefaciens PB6 for the prophylaxis or treatment of gastrointestinal and immuno-related diseases
|
EP1960518A2
(en)
|
2005-12-06 |
2008-08-27 |
Regents Of The University Of Minnesota |
Antibacterial agents
|
CN101374849A
(zh)
|
2005-12-24 |
2009-02-25 |
沃泰克斯药物股份有限公司 |
作为abc转运蛋白调控剂的喹啉-4-酮衍生物
|
BRPI0620578A2
(pt)
|
2005-12-27 |
2011-12-06 |
Jubilant Organosys Ltd |
composição farmacêutica que dissolve na boca e processo para o preparo da mesma
|
WO2007075946A1
(en)
|
2005-12-27 |
2007-07-05 |
Vertex Pharmaceuticals Incorporated |
Compounds useful in cftr assays and methods therewith
|
PL1993360T3
(pl)
|
2005-12-28 |
2017-08-31 |
Vertex Pharmaceuticals Incorporated |
Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
|
EP2016065B1
(en)
|
2005-12-28 |
2012-09-19 |
Vertex Pharmaceuticals Incorporated |
1-(benzo[d][1,3]dioxol-5-yl)-n-(phenyl)cyclopropane-carboxamide derivatives and related compounds as modulators of atp-binding cassette transporters for the treatment of cystic fibrosis
|
US7671221B2
(en)
|
2005-12-28 |
2010-03-02 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
UY30118A1
(es)
|
2006-01-31 |
2007-06-29 |
Tanabe Seiyaku Co |
Compueto amina trisustituido
|
MX2008011633A
(es)
|
2006-03-13 |
2008-12-16 |
Activx Biosciences Inc |
Aminoquinolonas como inhibidores de gsk-3.
|
WO2007106957A1
(en)
|
2006-03-21 |
2007-09-27 |
Laboratoires Smb S.A. |
Multiple units controlled-release floating dosage forms
|
US10022352B2
(en)
|
2006-04-07 |
2018-07-17 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US7645789B2
(en)
|
2006-04-07 |
2010-01-12 |
Vertex Pharmaceuticals Incorporated |
Indole derivatives as CFTR modulators
|
RU2451018C2
(ru)
|
2006-04-07 |
2012-05-20 |
Вертекс Фармасьютикалз Инкорпорейтед |
Модуляторы атф-связывающих кассетных транспортеров
|
EP2687516A1
(en)
|
2006-04-20 |
2014-01-22 |
Janssen Pharmaceutica N.V. |
Inhibitors of C-FMS Kinase
|
CN101478964B
(zh)
|
2006-05-12 |
2012-02-29 |
沃泰克斯药物股份有限公司 |
N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物
|
JP2010502762A
(ja)
|
2006-09-12 |
2010-01-28 |
グラクソ グループ リミテッド |
ファクターXa阻害剤を含有する複数のミニ錠剤を含む、医薬組成物
|
CN103159760B
(zh)
|
2006-11-03 |
2016-06-08 |
沃泰克斯药物股份有限公司 |
作为cftr调控剂的氮杂吲哚衍生物
|
US8563573B2
(en)
|
2007-11-02 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Azaindole derivatives as CFTR modulators
|
US7754739B2
(en)
|
2007-05-09 |
2010-07-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
MX2009006806A
(es)
|
2006-12-22 |
2009-08-27 |
Vertex Pharma |
Secado por rocio fluidizado.
|
WO2008083130A2
(en)
|
2006-12-26 |
2008-07-10 |
Dr. Reddy's Laboratories Limited |
Amorphous and crystalline form a of carvedilol phosphate
|
ES2442901T3
(es)
*
|
2007-04-18 |
2014-02-14 |
Cornerstone Pharmaceuticals, Inc. |
Derivados de ácido lipoico
|
AU2008251504B2
(en)
|
2007-05-09 |
2013-07-18 |
Vertex Pharmaceuticals Incorporated |
Modulators of CFTR
|
HUE025553T2
(en)
|
2007-05-25 |
2016-02-29 |
Vertex Pharma |
CFTR modulators
|
JP4834699B2
(ja)
|
2007-07-30 |
2011-12-14 |
田辺三菱製薬株式会社 |
医薬組成物
|
JP4846769B2
(ja)
|
2007-07-30 |
2011-12-28 |
田辺三菱製薬株式会社 |
医薬組成物
|
WO2009023509A2
(en)
|
2007-08-09 |
2009-02-19 |
Vertex Pharmaceuticals Incorporated |
Therapeutic combinations useful in treating cftr related diseases
|
NZ583420A
(en)
|
2007-08-24 |
2012-06-29 |
Vertex Pharma |
Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
|
CA2699382C
(en)
|
2007-09-14 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
JP2010540417A
(ja)
|
2007-09-14 |
2010-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
|
EP3012250B1
(en)
|
2007-11-16 |
2017-11-08 |
Vertex Pharmaceuticals Incorporated |
Isoquinoline modulators of atp-binding cassette transporters
|
SI2639222T1
(sl)
|
2007-12-07 |
2016-12-30 |
Vertex Pharmaceuticals Incorporated |
Proces za izdelavo cikloalkilkarboksiamido-piridin benzojskih kislin
|
US8507534B2
(en)
|
2007-12-07 |
2013-08-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
BRPI0820681A2
(pt)
|
2007-12-07 |
2019-09-24 |
Vertex Pharma |
formulações de ácido 3-(6-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilperidin-2-il)benzoico
|
US20100036130A1
(en)
|
2007-12-07 |
2010-02-11 |
Vertex Pharmaceuticals Incorporated |
Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
|
CA2709301C
(en)
|
2007-12-13 |
2016-05-10 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
NZ620944A
(en)
|
2008-02-28 |
2015-02-27 |
Vertex Pharma |
Heteroaryl derivatives as cftr modulators
|
SI2615085T1
(sl)
|
2008-03-31 |
2015-11-30 |
Vertex Pharmaceuticals Incorporated |
Piridilni derivati kot cftr-modulatorji
|
US20100256184A1
(en)
|
2008-08-13 |
2010-10-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition and administrations thereof
|
CA2733908C
(en)
|
2008-08-13 |
2017-05-30 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical composition comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
WO2010025126A1
(en)
|
2008-08-26 |
2010-03-04 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Rapidly disintegrating tablets comprising lipase, amylase, and protease
|
AU2009296271A1
(en)
|
2008-09-29 |
2010-04-01 |
Vertex Pharmaceuticals Incorporated |
Dosage units of 3-(6-(1-(2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
CN102202649A
(zh)
|
2008-10-07 |
2011-09-28 |
Mpex医药有限公司 |
用于改进的药物动力学的氟喹诺酮气雾剂制剂
|
HUE050147T2
(hu)
|
2008-10-07 |
2020-11-30 |
Horizon Orphan Llc |
Tüdõgyulladás csökkentése levofloxacin belélegzése útján
|
US9333235B2
(en)
|
2008-10-22 |
2016-05-10 |
Trustees Of Dartmouth College |
Combination therapy and kit for the prevention and treatment of cystic fibrosis
|
JP5645835B2
(ja)
|
2008-10-23 |
2014-12-24 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
N−(4−(7−アザビシクロ[2.2.1]ヘプタン−7−イル)−2−(トリフルオロメチル)フェニル)−4−オキソ−5−(トリフルオロメチル)−1,4−ジヒドロキノリン−3−カルボキサミドの固体形態
|
US8513282B2
(en)
|
2008-10-23 |
2013-08-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
US20110257223A1
(en)
|
2008-10-23 |
2011-10-20 |
Vertex Pharmaceuticals Incorporated |
Modulators of Cystic Fibrosis Transmembrane Conductance Regulator
|
CA2742042A1
(en)
|
2008-10-23 |
2010-04-29 |
Vertex Pharmaceuticals Incorporated |
Modulators of cystic fibrosis transmembrane conductance regulator
|
UA104876C2
(uk)
|
2008-11-06 |
2014-03-25 |
Вертекс Фармасьютікалз Інкорпорейтед |
Модулятори atф-зв'язувальних касетних транспортерів
|
CN102272127A
(zh)
|
2008-11-06 |
2011-12-07 |
弗特克斯药品有限公司 |
Atp-结合盒转运蛋白调节剂
|
JP5699090B2
(ja)
|
2008-12-30 |
2015-04-08 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
嚢胞性線維症膜コンダクタンス調節因子のモジュレーター
|
GB201111244D0
(en)
|
2011-06-30 |
2011-08-17 |
Konink Nl Akademie Van Wetenschappen Knaw |
Culture media for stem cells
|
CN102439151A
(zh)
|
2009-03-19 |
2012-05-02 |
默沙东公司 |
使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制
|
EP2408458A1
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
EP2408916A2
(en)
|
2009-03-19 |
2012-01-25 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120029054A1
(en)
|
2009-03-19 |
2012-02-02 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of GATA Binding Protein 3 (GATA3) Gene Expression Using Short Intefering Nucleic Acid (siNA)
|
KR101955863B1
(ko)
|
2009-03-20 |
2019-03-07 |
버텍스 파마슈티칼스 인코포레이티드 |
낭성 섬유증 막횡단 전도도 조절자의 조정자의 제조 방법
|
ES2683633T3
(es)
|
2009-03-20 |
2018-09-27 |
Vertex Pharmaceuticals Incorporated |
Moduladores de regulador de conductancia transmembrana de la fibrosis quística
|
EP2411520A2
(en)
|
2009-03-27 |
2012-02-01 |
Merck Sharp&Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
US20120010272A1
(en)
|
2009-03-27 |
2012-01-12 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Apoptosis Signal-Regulating Kinase 1 (ASK1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
WO2010111503A2
(en)
|
2009-03-27 |
2010-09-30 |
Merck Sharp & Dohme Corp. |
RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
|
US20120004282A1
(en)
|
2009-03-27 |
2012-01-05 |
Merck Sharp & Dohme Corp, |
RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
JP2012521762A
(ja)
|
2009-03-27 |
2012-09-20 |
メルク・シャープ・エンド・ドーム・コーポレイション |
低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害
|
US20120022142A1
(en)
|
2009-03-27 |
2012-01-26 |
Merck Sharp & Dohme Corp. |
RNA Interference Mediated Inhibition of Signal Transducer and Activator of Transcription 1 (STAT1) Gene Expression Using Short Interfering Nucleic Acid (siNA)
|
BR112012006031A2
(pt)
|
2009-09-17 |
2019-09-24 |
Vertex Pharma |
processo para preparação de compostos azabicíclicos.
|
CN102665715A
(zh)
|
2009-10-22 |
2012-09-12 |
沃泰克斯药物股份有限公司 |
治疗囊性纤维化和其他慢性疾病的组合物
|
CN102666546B
(zh)
|
2009-10-23 |
2015-09-09 |
沃泰克斯药物股份有限公司 |
N-(4-(7-氮杂双环[2.2.1]庚-7-基)-2-(三氟甲基)苯基)-4-氧代-5-(三氟甲基)-1,4-二氢喹啉-3-甲酰胺的固体形式
|
BR112012009583A2
(pt)
|
2009-10-23 |
2015-09-29 |
Vertex Pharma |
processo para preparação de moduladores de regulador de condutância de transmembrana de fibrose cística
|
US20130004477A1
(en)
|
2009-10-26 |
2013-01-03 |
Zhe Lu |
Methods for Treating Inflammation and Oxidative Stress Related Diseases
|
WO2011072275A2
(en)
|
2009-12-11 |
2011-06-16 |
Nono, Inc. |
Agents and methods for treating ischemic and other diseases
|
US20110183948A1
(en)
|
2010-01-15 |
2011-07-28 |
Infinity Pharmaceuticals, Inc. |
Treatment of fibrotic conditions using hedgehog inhibitors
|
US20150152348A1
(en)
|
2010-02-26 |
2015-06-04 |
Sharps Compliance, Inc. |
Systems and methods for collecting, transporting and repurposing or destroying unused pharmaceuticals
|
EP2547658A1
(en)
|
2010-03-19 |
2013-01-23 |
Vertex Pharmaceuticals Incorporated |
Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
US8802868B2
(en)
|
2010-03-25 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
|
US20110251253A1
(en)
|
2010-03-25 |
2011-10-13 |
Vertex Pharmaceuticals Incorporated |
Solid forms of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide
|
CA2795748C
(en)
|
2010-04-07 |
2020-12-08 |
Vertex Pharmaceuticals Incorporated |
Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
PL3150198T3
(pl)
|
2010-04-07 |
2022-01-17 |
Vertex Pharmaceuticals Incorporated |
Kompozycje farmaceutyczne kwasu 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioksol-5-ilo)cyklopropanokarboksamido)-3-metylopirydyn-2-ylo)benzoesowego i ich podawanie
|
NZ603042A
(en)
|
2010-04-22 |
2015-02-27 |
Vertex Pharma |
Pharmaceutical compositions comprising cftr modulators and administrations thereof
|
EP2560651A1
(en)
|
2010-04-22 |
2013-02-27 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
AU2011242454A1
(en)
|
2010-04-22 |
2012-11-08 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
EP3045452A1
(en)
|
2010-04-22 |
2016-07-20 |
Vertex Pharmaceuticals Inc. |
Process of producing cycloalkylcarboxamido-indole compounds
|
WO2011146901A1
(en)
|
2010-05-20 |
2011-11-24 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions and administrations thereof
|
TW201202250A
(en)
|
2010-05-20 |
2012-01-16 |
Vertex Pharma |
Processes for producing modulators of cystic fibrosis transmembrane conductance regulator
|
US8563593B2
(en)
|
2010-06-08 |
2013-10-22 |
Vertex Pharmaceuticals Incorporated |
Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
|
US20120164080A1
(en)
|
2010-06-24 |
2012-06-28 |
Meritage Pharma, Inc. |
Methods of treatment for esophageal inflammation
|
CN103153287A
(zh)
|
2010-08-23 |
2013-06-12 |
弗特克斯药品有限公司 |
(R)-1-(2,2-二氟苯并[d][1,3]间二氧杂环戊烯-5-基)-N-(1-(2,3-二羟基丙基)-6-氟-2-(1-羟基-2-甲基丙-2-基)-1H-吲哚-5-基)环丙烷甲酰胺的药物组合物及其施用
|
JP2013536251A
(ja)
|
2010-08-27 |
2013-09-19 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
薬学的組成物およびその投与
|
WO2012030664A1
(en)
|
2010-08-30 |
2012-03-08 |
Pulmatrix, Inc. |
Dry powder formulations and methods for treating pulmonary diseases
|
US20130164338A1
(en)
|
2010-08-30 |
2013-06-27 |
Pulmatrix, Inc. |
Treatment of cystic fibrosis using calcium lactate, leucine and sodium chloride in a respiraple dry powder
|
US9050339B2
(en)
|
2010-09-17 |
2015-06-09 |
Novartis Ag |
Pyrazine derivatives as ENaC blockers
|
US8372845B2
(en)
|
2010-09-17 |
2013-02-12 |
Novartis Ag |
Pyrazine derivatives as enac blockers
|
US8802700B2
(en)
|
2010-12-10 |
2014-08-12 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-Binding Cassette transporters
|
US20140031547A1
(en)
|
2010-12-14 |
2014-01-30 |
Electrophoretics Limited |
CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
|
US9249087B2
(en)
|
2011-02-01 |
2016-02-02 |
The Board Of Trustees Of The University Of Illinois |
HDAC inhibitors and therapeutic methods using the same
|
WO2012148953A1
(en)
|
2011-04-25 |
2012-11-01 |
Stc.Unm |
Solid compositions for pharmaceutical use
|
WO2012154888A1
(en)
|
2011-05-09 |
2012-11-15 |
Proteostasis Therapeutics, Inc. |
Compounds for treating protein folding disorders
|
AU2012255711B2
(en)
|
2011-05-18 |
2017-05-04 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated derivatives of ivacaftor
|
US8945605B2
(en)
|
2011-06-07 |
2015-02-03 |
Parion Sciences, Inc. |
Aerosol delivery systems, compositions and methods
|
ITMI20111068A1
(it)
|
2011-06-14 |
2012-12-15 |
Azienda Ospedaliera Universitaria I Ntegrata Di Ve |
Trimetilangelicina come correttore di cftr in cellule dell'epitelio bronchiale
|
AR086745A1
(es)
|
2011-06-27 |
2014-01-22 |
Parion Sciences Inc |
3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
|
KR101317656B1
(ko)
|
2011-06-30 |
2013-10-15 |
연세대학교 산학협력단 |
복제효소 인산화를 조절하는 신규 c형 간염 예방 또는 치료용 조성물
|
CN103930422A
(zh)
|
2011-07-19 |
2014-07-16 |
无限药品股份有限公司 |
杂环化合物及其用途
|
WO2013012918A1
(en)
|
2011-07-19 |
2013-01-24 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
CA2846431A1
(en)
|
2011-08-29 |
2013-03-07 |
Infinity Pharmaceuticals Inc. |
Heterocyclic compounds and uses thereof
|
WO2013052844A1
(en)
|
2011-10-07 |
2013-04-11 |
Pulmatrix, Inc. |
Methods for treating and diagnosing respiratory tract infections
|
AU2012332225A1
(en)
|
2011-11-02 |
2014-05-15 |
Vertex Pharmaceuticals Incorporated |
Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases
|
HUE034929T2
(en)
|
2011-11-02 |
2018-03-28 |
Boehringer Ingelheim Int |
Heterocyclic compounds, pharmaceuticals containing such compounds, their use and methods for their preparation
|
US9580409B2
(en)
|
2011-11-07 |
2017-02-28 |
Sunovion Pharmaceuticals, Inc. |
Modulators of opioid receptors and methods of use thereof
|
AU2012335714B2
(en)
|
2011-11-08 |
2017-04-13 |
Vertex Pharmaceuticals Incorporated |
Modulators of ATP-binding cassette transporters
|
US20140127901A1
(en)
|
2012-11-08 |
2014-05-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Low-k damage free integration scheme for copper interconnects
|
WO2013090833A1
(en)
|
2011-12-16 |
2013-06-20 |
Tarix Pharmaceuticals Ltd. |
Angiotensins for treatment of fibrosis
|
CA2859614C
(en)
|
2011-12-19 |
2020-08-25 |
Koninklijke Nederlandse Akademie Van Wetenschappen |
A rapid quantitative assay to measure cftr function in a primary intestinal culture model
|
US8859559B2
(en)
|
2011-12-20 |
2014-10-14 |
Boehringer Ingelheim International Gmbh |
Substituted pyrazines and their use in the treatment of disease
|
US20130186801A1
(en)
|
2012-01-25 |
2013-07-25 |
Vertex Pharmaceuticals Incorporated |
Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
|
IL265430B2
(en)
|
2012-02-27 |
2024-08-01 |
Vertex Pharma |
Pharmaceutical preparations containing a solid dispersion of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide and uses thereof
|
JP2015509788A
(ja)
|
2012-02-29 |
2015-04-02 |
パルマトリックス,インコーポレイテッド |
吸入に適した乾燥粉末
|
US8809340B2
(en)
|
2012-03-19 |
2014-08-19 |
Novartis Ag |
Crystalline form
|
CN104619321A
(zh)
|
2012-04-06 |
2015-05-13 |
Uab研究基金会 |
用于增加cftr活性的方法
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2013157018A1
(en)
|
2012-04-18 |
2013-10-24 |
Indian Institute Of Technology Madras |
A process for the preparation of the core structure in quinolone and napthyridone class of antibiotics
|
US8674108B2
(en)
|
2012-04-20 |
2014-03-18 |
Vertex Pharmaceuticals Incorporated |
Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
|
EP2659890A1
(en)
|
2012-04-30 |
2013-11-06 |
Orphan Synergy Europe - Pharma |
Methods and compositions for the treatment of fibrosis
|
ES2656321T3
(es)
|
2012-05-17 |
2018-02-26 |
I.E.R.F.C. European Institute For Cystic Fibrosis Research |
Terapia combinada para fibrosis quística
|
FR2990859B1
(fr)
|
2012-05-24 |
2014-05-23 |
Gaetan Terrasse |
Utilisation d'une molecule h4 agoniste pour le traitement de la mucoviscidose
|
JP6204977B2
(ja)
|
2012-05-25 |
2017-09-27 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
三級アミン、前記アミンを含む薬物、その使用及びその調製方法
|
WO2013181530A1
(en)
|
2012-06-01 |
2013-12-05 |
Icahn School Of Medicine At Mount Sinai |
Ceramide levels in the treatment and prevention of infections
|
DE102012209523A1
(de)
|
2012-06-06 |
2013-12-12 |
Osram Opto Semiconductors Gmbh |
Hauptgruppenmetallkomplexe als p-Dotanden für organische elektronische Matrixmaterialien
|
DE102012209520A1
(de)
|
2012-06-06 |
2013-12-12 |
Osram Opto Semiconductors Gmbh |
Metallkomplexe als p-Dotanden für organische elektronische Matrixmaterialien
|
CA2874851A1
(en)
|
2012-06-08 |
2013-12-12 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for the treatment of cftr-mediated disorders
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
US20150209448A1
(en)
|
2012-07-12 |
2015-07-30 |
Proqr Therapeutics N.V. |
Exon replacement with stabilized artificial rnas
|
DK3103872T3
(en)
|
2012-07-12 |
2018-10-22 |
Proqr Therapeutics Ii Bv |
OLIGONUCLEOTIDES TO MAKE A CHANGE IN THE SEQUENCE OF A TARGET RNA MOLECULE IN A LIVING CELL
|
AR092857A1
(es)
|
2012-07-16 |
2015-05-06 |
Vertex Pharma |
Composiciones farmaceuticas de (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)-n-(1-(2,3-dihidroxipropil)-6-fluoro-2-(1-hidroxi-2-metilpropan-2-il)-1h-indol-5-il)ciclopropancarboxamida y administracion de las mismas
|
EP2875001B1
(en)
|
2012-07-18 |
2019-01-09 |
Sunshine Lake Pharma Co., Ltd. |
Nitrogenous heterocyclic derivatives and their application in drugs
|
CN104822661B
(zh)
|
2012-07-20 |
2017-05-31 |
拜耳药业股份公司 |
5‑氨基四氢喹啉‑2‑羧酸及其用途
|
CA2879456A1
(en)
|
2012-07-20 |
2014-01-23 |
Bayer Pharma Aktiengesellschaft |
Substituted aminoindane- and aminotetralincarboxylic acids and use thereof
|
AU2013295549B2
(en)
|
2012-07-27 |
2018-04-19 |
Izumi Technology, Llc |
Efflux inhibitor compositions and methods of treatment using the same
|
EP2882426A1
(en)
|
2012-08-13 |
2015-06-17 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for treatment of cystic fibrosis
|
US9566310B2
(en)
|
2012-09-10 |
2017-02-14 |
Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno |
Methods of treating muscular dystrophy
|
EP2897940B1
(en)
|
2012-09-24 |
2019-05-01 |
Boehringer Ingelheim International GmbH |
Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof
|
AU2013319788B2
(en)
|
2012-09-24 |
2019-04-11 |
Yissum Reasearch Development Company of the Hebrew University Of Jerusalem Ltd. |
Restoration of the CFTR function by splicing modulation
|
WO2014058974A1
(en)
|
2012-10-10 |
2014-04-17 |
Emory University |
Methods of managing inflammation using glycolysis pathway inhibitors
|
US20150258043A1
(en)
|
2012-10-15 |
2015-09-17 |
Yeda Research And Development Co. Ltd. |
Use of sphingoid long chain bases and their analogs in treating and preventing bacterial infections
|
US20140120060A1
(en)
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of rheumatoid arthritis and asthma using pi3 kinase inhibitors
|
BR112015009913B1
(pt)
|
2012-11-02 |
2023-04-11 |
Vertex Pharmaceuticals Incorporated |
Comprimido compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo, seu processo de preparação, kit e método de preparação de um grânulo compreendendo composto cristalino e dispersão sólida de composto substancialmente amorfo
|
JP6146990B2
(ja)
|
2012-11-16 |
2017-06-14 |
コンサート ファーマシューティカルズ インコーポレイテッド |
重水素化されたcftr増強物質
|
MY183582A
(en)
|
2012-11-19 |
2021-02-26 |
Vertex Pharmaceuticals Europe Ltd |
Deuterated cftr potentiators
|
CA2891965A1
(en)
|
2012-11-20 |
2014-05-30 |
Discoverybiomed, Inc. |
Small molecule bicyclic and tricyclic cftr correctors
|
AU2013348018A1
(en)
|
2012-11-20 |
2015-06-04 |
Discoverybiomed, Inc. |
Small molecule CFTR correctors
|
US10034988B2
(en)
|
2012-11-28 |
2018-07-31 |
Fontem Holdings I B.V. |
Methods and devices for compound delivery
|
WO2014086934A1
(en)
|
2012-12-05 |
2014-06-12 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Diagnosis of cystic fibrosis
|
EP2928532A4
(en)
|
2012-12-07 |
2016-06-29 |
Parion Sciences Inc |
NOSE CANNULA FOR THE ADMINISTRATION OF MEDICAMENTS IN AEROSOL FORM
|
BR112015014178A2
(pt)
|
2012-12-17 |
2017-07-11 |
Parion Sciences Inc |
compostos de 3,5-diamino-6-cloro-n-(n-(4-fenilbutil)carbamimidoil) pirazina-2- carboxamida
|
ME03000B
(me)
|
2012-12-21 |
2018-10-20 |
Plexxikon Inc |
Jedinjenja i metode modulacije kinaze i povezane indikacije
|
CN103044263A
(zh)
|
2013-01-14 |
2013-04-17 |
中国药科大学 |
一种治疗囊性纤维化药物的中间体的制备方法
|
US20140221424A1
(en)
|
2013-01-30 |
2014-08-07 |
Vertex Pharmaceuticals Incorporated |
Pharmaceutical compositions for use in the treatment of cystic fibrosis
|
US9550735B2
(en)
|
2013-01-31 |
2017-01-24 |
Glenmark Pharmaceuticals Limited |
Process for the preparation of ivacaftor and solvates thereof
|
WO2014125506A2
(en)
|
2013-02-15 |
2014-08-21 |
Laurus Labs Private Limited |
A process for the preparation of ivacaftor and its intermediates
|
JP2016517266A
(ja)
|
2013-02-18 |
2016-06-16 |
ユニバーシティー ヘルス ネットワーク |
多能性幹細胞から肝細胞及び胆管細胞を作製する方法
|
CN104030981A
(zh)
|
2013-03-06 |
2014-09-10 |
上海特化医药科技有限公司 |
Ivacaftor的制备方法及其中间体
|
EP2968285A4
(en)
|
2013-03-13 |
2016-12-21 |
Flatley Discovery Lab |
COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
|
JP6545148B2
(ja)
|
2013-03-13 |
2019-07-17 |
フラットリー ディスカバリー ラブ,エルエルシー |
ピリダジノン化合物及び嚢胞性線維症の治療のための方法
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
MX2015013040A
(es)
|
2013-03-15 |
2016-05-24 |
Orpro Therapeutics Inc |
Producto y proceso para normalización de la viscosidad del moco.
|
NZ629037A
(en)
|
2013-03-15 |
2017-04-28 |
Infinity Pharmaceuticals Inc |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
US20140296164A1
(en)
|
2013-03-29 |
2014-10-02 |
Calista Therapeutics, Inc. |
Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand
|
CN103224466A
(zh)
|
2013-04-15 |
2013-07-31 |
北京大学 |
具有β-分泌酶抑制功能的化合物及其制备方法与应用
|
US20140358576A1
(en)
|
2013-05-15 |
2014-12-04 |
Adverse Events, Inc. |
System and method for surveillance and evaluation of safety risks associated with medical interventions
|
WO2014186704A2
(en)
|
2013-05-17 |
2014-11-20 |
N30 Pharmaceuticals, Inc. |
Novel compounds for the treatment of cystic fibrosis
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
WO2014210159A1
(en)
|
2013-06-26 |
2014-12-31 |
Proteostasis Therapeutics, Inc. |
Methods of modulating cftr activity
|
EP3022197B1
(en)
|
2013-07-15 |
2017-09-06 |
Boehringer Ingelheim International GmbH |
Novel tetra- and pentasubstituted benzimidazolium compounds
|
WO2015007516A1
(en)
|
2013-07-15 |
2015-01-22 |
Boehringer Ingelheim International Gmbh |
Novel 5-substituted benzimidazolium compounds
|
JP6461134B2
(ja)
|
2013-07-15 |
2019-01-30 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規ベンゾイミダゾリウム化合物
|
EP3024455A1
(en)
|
2013-07-25 |
2016-06-01 |
Bayer Pharma Aktiengesellschaft |
Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
|
EP2835423A1
(en)
|
2013-08-09 |
2015-02-11 |
Commissariat à l'Énergie Atomique et aux Énergies Alternatives |
Ligase E3 RNF185 inhibitors and uses thereof
|
ES2716092T3
(es)
|
2013-09-12 |
2019-06-10 |
Inst Nat Sante Rech Med |
Métodos y composiciones farmacéuticas para el tratamiento de fibrosis quística
|
US20150099270A1
(en)
|
2013-10-04 |
2015-04-09 |
Thomas C. DOWLING |
Method of screening pharmaceuticals for drug interactions and nephrotoxicity
|
SG11201602445SA
(en)
|
2013-10-04 |
2016-04-28 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
FR3011467B1
(fr)
|
2013-10-08 |
2016-02-12 |
Centre Nat Rech Scient |
Composes et compositions comprenant de tels composes pour la prevention ou le traitement des dyslipidemies
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160229778A1
(en)
|
2013-11-08 |
2016-08-11 |
Board Of Regents, The University Of Texas System |
Direct b-arylation of carbonyl compounds
|
JP6963896B2
(ja)
|
2013-11-12 |
2021-11-10 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Cftr媒介性疾患の処置のための医薬組成物を調製する方法
|
AU2014351028B2
(en)
|
2013-11-13 |
2018-07-12 |
Apotex Inc. |
Solid forms of Ivacaftor and processes for the preparation thereof
|
US10626156B2
(en)
|
2013-12-06 |
2020-04-21 |
Jie Han |
Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
|
WO2015090232A1
(en)
|
2013-12-19 |
2015-06-25 |
Sunshine Lake Pharma Co., Ltd. |
Nitrogenous heterocyclic derivatives and their application in drugs
|
WO2015100025A1
(en)
|
2013-12-23 |
2015-07-02 |
Nitric Solutions Inc. |
Cystic fibrosis treatment comprising nitric oxide
|
PL3698832T3
(pl)
|
2014-01-22 |
2023-01-30 |
Fontem Ventures B.V. |
Sposoby i urządzenia do łagodzenia potrzeby palenia
|
EA201691582A1
(ru)
|
2014-02-07 |
2017-01-30 |
Оспекс Фармасьютикалз, Инк. |
Новые фармацевтические препараты
|
WO2015128882A2
(en)
|
2014-02-27 |
2015-09-03 |
Msn Laboratories Private Limited |
Crystalline forms of n-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide and process for the preparation thereof
|
CN103787968B
(zh)
|
2014-02-27 |
2016-04-13 |
上海湖发化学技术有限公司 |
化合物的制备方法
|
CA2942386A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
CA2942387A1
(en)
|
2014-03-13 |
2015-09-17 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr actvity
|
WO2015143012A1
(en)
|
2014-03-19 |
2015-09-24 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
HRP20230709T1
(hr)
|
2014-04-15 |
2023-10-13 |
Vertex Pharmaceuticals Incorporated |
Farmaceutski pripravci za liječenje bolesti povezanih s regulatorom provodljivosti transmembrane cistične fibroze
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
CA2947982C
(en)
|
2014-05-08 |
2022-11-29 |
Phasebio Pharmaceuticals, Inc. |
Methods and compositions for treating cystic fibrosis
|
EP3142701B1
(en)
|
2014-05-12 |
2018-06-27 |
Verona Pharma PLC |
New treatment
|
WO2015175773A1
(en)
|
2014-05-15 |
2015-11-19 |
Celgene Corporation |
Use of pde4 inhibitors and combinations thereof for the treatment of cystic fibrosis
|
WO2015175956A1
(en)
|
2014-05-16 |
2015-11-19 |
Celgene Corporation |
Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
|
WO2015179369A1
(en)
|
2014-05-20 |
2015-11-26 |
Infinity Pharmaceuticals, Inc. |
Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors
|
WO2015196071A1
(en)
|
2014-06-19 |
2015-12-23 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions and methods of increasing cftr activity
|
EP3177272A1
(en)
|
2014-08-04 |
2017-06-14 |
Sandoz AG |
Aqueous granulation process for amorphous poorly water soluble drugs
|
CN106573006A
(zh)
|
2014-08-21 |
2017-04-19 |
葛兰素史密斯克莱知识产权发展有限公司 |
作为药物的rip1激酶抑制剂杂环酰胺
|
GB201415381D0
(en)
|
2014-08-29 |
2014-10-15 |
Algipharma As |
Inhalable powder formulations of alginate oligomers
|
CN104725628B
(zh)
|
2014-10-01 |
2018-04-17 |
厦门赛诺邦格生物科技股份有限公司 |
一种含可降解基团的单一官能化支化聚乙二醇、制备方法及其生物相关物质
|
CN104530413B
(zh)
|
2014-10-01 |
2017-08-25 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物修饰的生物相关物质
|
CN104530417B
(zh)
|
2014-10-01 |
2017-09-08 |
厦门赛诺邦格生物科技股份有限公司 |
一种多官能化h型聚乙二醇衍生物及其制备方法
|
CN104530415B
(zh)
|
2014-10-01 |
2017-09-01 |
厦门赛诺邦格生物科技股份有限公司 |
一种异官能化y型聚乙二醇衍生物、制备方法及其生物相关物质
|
US9855249B2
(en)
|
2014-10-02 |
2018-01-02 |
Flatley Discovery Lab, Llc |
Isoxazole compounds and methods for the treatment of cystic fibrosis
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
UA125245C2
(uk)
|
2014-10-06 |
2022-02-09 |
Вертекс Фармасьютикалз Інкорпорейтед |
Модулятори регулятора трансмембранної провідності при муковісцидозі
|
KR20170095814A
(ko)
|
2014-10-06 |
2017-08-23 |
플랫틀리 디스커버리 랩, 엘엘씨 |
트라이아졸로피리딘 화합물 및 낭성 섬유증의 치료 방법
|
AU2015330923B2
(en)
|
2014-10-07 |
2020-03-12 |
Vertex Pharmaceuticals Incorporated |
Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
|
EP3204010A1
(en)
|
2014-10-08 |
2017-08-16 |
Nivalis Therapeutics, Inc. |
Methods for the treatment of cystic fibrosis
|
US20160108406A1
(en)
|
2014-10-08 |
2016-04-21 |
University Of Iowa Research Foundation |
Method of regulating cftr expression and processing
|
GB201418892D0
(en)
|
2014-10-23 |
2014-12-10 |
Proqr Therapeutics B V |
DNA editing
|
WO2016062269A1
(zh)
|
2014-10-24 |
2016-04-28 |
朗齐生物医学股份有限公司 |
阿那格雷在用于制备治疗癌症的医药组合物中的用途
|
AU2015339196A1
(en)
|
2014-10-31 |
2017-05-11 |
Abbvie S.A.R.L. |
Substituted tetrahydropyrans and method of use
|
LT3212189T
(lt)
|
2014-10-31 |
2020-11-25 |
Abbvie Overseas S.A R.L. |
Pakeisti chromanai ir naudojimo būdas
|
WO2016077413A1
(en)
|
2014-11-12 |
2016-05-19 |
Trustees Of Dartmouth College |
Dab2 inhibitors for the prevention and treatment of cystic fibrosis
|
WO2016075703A2
(en)
|
2014-11-13 |
2016-05-19 |
Laurus Labs Private Limited |
An improved process for preparation of 5-amino-2,4-di-tert- butylphenol or an acid addition salt thereof
|
CA2968130C
(en)
|
2014-11-18 |
2022-08-16 |
Vertex Pharmaceuticals Incorporated |
Process of conducting high throughput testing high performance liquid chromatography
|
MA41031A
(fr)
|
2014-11-26 |
2017-10-03 |
Catabasis Pharmaceuticals Inc |
Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie
|
WO2016086136A1
(en)
|
2014-11-26 |
2016-06-02 |
Catabasis Pharmaceuticals, Inc. |
Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders
|
US10414768B2
(en)
|
2014-12-05 |
2019-09-17 |
Centre National De La Recherche Scientifique (Cnrs) |
Compounds for treating cystic fibrosis
|
EP3229791A4
(en)
|
2014-12-09 |
2018-09-26 |
Laurus Labs Limited |
Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
|
WO2016094904A1
(en)
|
2014-12-12 |
2016-06-16 |
Celcuity Llc |
Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients
|
CA2971850A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
WO2016105468A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
MA41253A
(fr)
|
2014-12-23 |
2017-10-31 |
Proteostasis Therapeutics Inc |
Composés, compositions et procédés pour augmenter l'activité du cftr
|
CA2971855A1
(en)
|
2014-12-23 |
2016-06-30 |
Proteostasis Therapeutics, Inc. |
Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
|
CN107406488B
(zh)
|
2014-12-24 |
2021-08-31 |
凯思生物技术公司 |
用于治疗呼吸系统疾病的新型PI3Kγ抑制剂肽
|
CN107106873A
(zh)
|
2015-01-09 |
2017-08-29 |
吉利德阿波罗公司 |
用于治疗非酒精性脂肪肝病的acc抑制剂组合治疗
|
US20180147187A1
(en)
|
2015-01-12 |
2018-05-31 |
Proteostasis Therapeutics, Inc. |
Compounds, compositions, and methods for increasing cftr activity
|
EP3256150B1
(en)
|
2015-02-09 |
2020-12-09 |
SciClone Pharmaceuticals International Ltd. |
Thymosin alpha 1 for use in treatment of cystic fibrosis
|
DE102015002820A1
(de)
|
2015-03-02 |
2016-09-08 |
Marco Schmidt |
Verfahren zur Speicherung genetischer Daten der personalisierten Medizin
|
CN104725314A
(zh)
|
2015-03-23 |
2015-06-24 |
上海皓元化学科技有限公司 |
一种Ivacaftor的新晶型及其制备方法
|
US10196384B2
(en)
|
2015-03-31 |
2019-02-05 |
Vertex Pharmaceuticals (Europe) Limited |
Deuterated CFTR modulators
|
GB201507926D0
(en)
|
2015-05-08 |
2015-06-24 |
Proqr Therapeutics N V |
Improved treatments using oligonucleotides
|
WO2016181414A1
(en)
|
2015-05-12 |
2016-11-17 |
Council Of Scientific & Industrial Research |
Process for the synthesis of ivacaftor and related compounds
|
TWI730959B
(zh)
|
2015-05-19 |
2021-06-21 |
英商葛蘭素史克智慧財產發展有限公司 |
作為激酶抑制劑之雜環醯胺
|
CA3021752A1
(en)
|
2015-06-11 |
2016-12-15 |
Aizant Drug Research Solutions Private Limited |
Nanoparticulate ivacaftor formulations
|
CN105130891B
(zh)
|
2015-08-05 |
2018-03-23 |
上海皓元医药股份有限公司 |
一种Ivacaftor的合成方法及其中间体
|
CN105153105B
(zh)
|
2015-08-15 |
2018-01-19 |
浙江永宁药业股份有限公司 |
1‑(2,2‑二氟苯并[d][1,3]二氧杂环戊烯‑5‑基)环丙烷甲酸的合成方法及其中间体
|
CN105237414B
(zh)
|
2015-09-30 |
2017-03-22 |
浙江永宁药业股份有限公司 |
ivacaftor中间体及其制备方法和用途
|
CN105457038A
(zh)
|
2015-11-09 |
2016-04-06 |
东南大学 |
一种速释型药物磷脂化合物及其药物组合物
|
CN105884628B
(zh)
|
2016-06-06 |
2018-06-29 |
上海工程技术大学 |
2,4-二叔丁基-5-氨基酚的制备方法
|
US20180280349A1
(en)
|
2017-03-28 |
2018-10-04 |
Vertex Pharmaceuticals Incorporated |
Methods of treating cystic fibrosis in patients with residual function mutations
|